Which has preferable earnings and valuation, GKOS or AXGN?

AxoGen has lower revenue, but higher earnings than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 18.17 -$187.69M -$3.28 N/A AxoGen $238.11M 8.90 -$15.70M -$0.64 N/A

Is GKOS or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% AxoGen -13.21% -9.63% -6.26%

Does the media favor GKOS or AXGN?

In the previous week, Glaukos had 7 more articles in the media than AxoGen. MarketBeat recorded 12 mentions for Glaukos and 5 mentions for AxoGen. AxoGen's average media sentiment score of 0.91 beat Glaukos' score of 0.85 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AXGN or LQDA?

AxoGen has higher revenue and earnings than Liquidia. AxoGen is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 8.90 -$15.70M -$0.64 N/A Liquidia $158.32M 44.90 -$68.92M $0.14 571.00

Is AXGN or LQDA more profitable?

Liquidia has a net margin of 7.74% compared to AxoGen's net margin of -13.21%. Liquidia's return on equity of 46.82% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% Liquidia 7.74% 46.82% 7.06%

Does the media favor AXGN or LQDA?

In the previous week, Liquidia had 28 more articles in the media than AxoGen. MarketBeat recorded 33 mentions for Liquidia and 5 mentions for AxoGen. AxoGen's average media sentiment score of 0.91 beat Liquidia's score of 0.37 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BLCO or AXGN more profitable?

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% AxoGen -13.21% -9.63% -6.26%

Does the media favor BLCO or AXGN?

In the previous week, AxoGen had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for AxoGen and 1 mentions for Bausch + Lomb. AxoGen's average media sentiment score of 0.91 beat Bausch + Lomb's score of 0.44 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AXGN or STVN?

AxoGen currently has a consensus target price of $46.50, suggesting a potential upside of 16.69%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, AXGN or STVN?

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 8.90 -$15.70M -$0.64 N/A Stevanato Group €1.34B 4.34 €158.21M €0.59 32.57

Does the media prefer AXGN or STVN?

In the previous week, AxoGen had 2 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for AxoGen and 3 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.73 beat AxoGen's score of 0.91 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, LIVN or AXGN?

AxoGen has lower revenue, but higher earnings than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.19 -$242.47M $1.95 41.38 AxoGen $238.11M 8.90 -$15.70M -$0.64 N/A

Is LIVN or AXGN more profitable?

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% AxoGen -13.21% -9.63% -6.26%

Does the media favor LIVN or AXGN?

In the previous week, AxoGen had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for AxoGen and 2 mentions for LivaNova. LivaNova's average media sentiment score of 1.01 beat AxoGen's score of 0.91 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

AxoGen (AXGN) Competitors

$39.85 +0.07 (+0.18%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$39.76 -0.09 (-0.23%)

As of 07/17/2026 05:45 PM Eastern

Compare

AXGN vs. GKOS, LQDA, BLCO, STVN, and LIVN

Should you buy AxoGen stock or one of its competitors? MarketBeat compares AxoGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AxoGen include Glaukos (GKOS), Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does AxoGen compare to Glaukos?

Glaukos (NYSE:GKOS) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

AxoGen has lower revenue, but higher earnings than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	18.17	-$187.69M	-$3.28	N/A
AxoGen	$238.11M	8.90	-$15.70M	-$0.64	N/A

99.0% of Glaukos shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Glaukos had 7 more articles in the media than AxoGen. MarketBeat recorded 12 mentions for Glaukos and 5 mentions for AxoGen. AxoGen's average media sentiment score of 0.91 beat Glaukos' score of 0.85 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus target price of $154.85, suggesting a potential downside of 1.36%. AxoGen has a consensus target price of $46.50, suggesting a potential upside of 16.69%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
AxoGen	-13.21%	-9.63%	-6.26%

Glaukos has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Summary

Glaukos beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does AxoGen compare to Liquidia?

AxoGen (NASDAQ:AXGN) and Liquidia (NASDAQ:LQDA) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

AxoGen has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

In the previous week, Liquidia had 28 more articles in the media than AxoGen. MarketBeat recorded 33 mentions for Liquidia and 5 mentions for AxoGen. AxoGen's average media sentiment score of 0.91 beat Liquidia's score of 0.37 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AxoGen has higher revenue and earnings than Liquidia. AxoGen is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	8.90	-$15.70M	-$0.64	N/A
Liquidia	$158.32M	44.90	-$68.92M	$0.14	571.00

Liquidia has a net margin of 7.74% compared to AxoGen's net margin of -13.21%. Liquidia's return on equity of 46.82% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Liquidia	7.74%	46.82%	7.06%

AxoGen currently has a consensus target price of $46.50, suggesting a potential upside of 16.69%. Liquidia has a consensus target price of $68.88, suggesting a potential downside of 13.84%. Given AxoGen's higher probable upside, research analysts plainly believe AxoGen is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

Summary

Liquidia beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

AxoGen has lower revenue, but higher earnings than Bausch + Lomb. AxoGen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A
AxoGen	$238.11M	8.90	-$15.70M	-$0.64	N/A

Bausch + Lomb presently has a consensus target price of $18.00, suggesting a potential upside of 10.70%. AxoGen has a consensus target price of $46.50, suggesting a potential upside of 16.69%. Given AxoGen's stronger consensus rating and higher possible upside, analysts plainly believe AxoGen is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
AxoGen	-13.21%	-9.63%	-6.26%

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bausch + Lomb has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

In the previous week, AxoGen had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for AxoGen and 1 mentions for Bausch + Lomb. AxoGen's average media sentiment score of 0.91 beat Bausch + Lomb's score of 0.44 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AxoGen beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks.

How does AxoGen compare to Stevanato Group?

AxoGen (NASDAQ:AXGN) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, AxoGen had 2 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for AxoGen and 3 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.73 beat AxoGen's score of 0.91 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	8.90	-$15.70M	-$0.64	N/A
Stevanato Group	€1.34B	4.34	€158.21M	€0.59	32.57

AxoGen currently has a consensus target price of $46.50, suggesting a potential upside of 16.69%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Stevanato Group has a net margin of 11.76% compared to AxoGen's net margin of -13.21%. Stevanato Group's return on equity of 10.27% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Stevanato Group	11.76%	10.27%	6.08%

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 0.7% of Stevanato Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AxoGen has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Stevanato Group beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

LivaNova (NASDAQ:LIVN) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
AxoGen	-13.21%	-9.63%	-6.26%

AxoGen has lower revenue, but higher earnings than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.19	-$242.47M	$1.95	41.38
AxoGen	$238.11M	8.90	-$15.70M	-$0.64	N/A

In the previous week, AxoGen had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for AxoGen and 2 mentions for LivaNova. LivaNova's average media sentiment score of 1.01 beat AxoGen's score of 0.91 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

LivaNova currently has a consensus target price of $81.38, suggesting a potential upside of 0.84%. AxoGen has a consensus target price of $46.50, suggesting a potential upside of 16.69%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

LivaNova and AxoGen tied by winning 8 of the 16 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.12B	$7.63B	$6.87B	$12.40B
Dividend Yield	N/A	1.32%	2.67%	8.85%
P/E Ratio	-62.27	50.09	27.23	23.92
Price / Sales	8.90	49.29	529.67	91.80
Price / Cash	N/A	26.87	51.46	60.07
Price / Book	14.28	7.03	10.69	6.18
Net Income	-$15.70M	$162.30M	$3.59B	$332.29M
7 Day Performance	-1.80%	-2.22%	-2.20%	-2.05%
1 Month Performance	-11.13%	-1.20%	1.63%	-2.15%
1 Year Performance	253.28%	6.83%	25.59%	17.26%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	2.669 of 5 stars	$39.85 +0.2%	$46.50 +16.7%	+242.6%	$2.12B	$238.11M	N/A	450	News Coverage Analyst Downgrade
GKOS Glaukos	1.5805 of 5 stars	$148.84 +0.1%	$150.62 +1.2%	+58.6%	$8.78B	$507.44M	N/A	1,094	News Coverage Analyst Forecast
LQDA Liquidia	2.6303 of 5 stars	$79.77 +0.7%	$68.88 -13.7%	+447.5%	$7.01B	$158.32M	563.08	50	Insider Trade
BLCO Bausch + Lomb	3.5171 of 5 stars	$17.31 +1.2%	$17.83 +3.0%	+14.6%	$6.12B	$5.10B	N/A	13,000
STVN Stevanato Group	3.0488 of 5 stars	€19.39 +0.6%	N/A	-24.7%	€5.86B	€1.20B	32.81	6,010	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors